Barclays »

Nektar Therapeutics shares owned by Barclays

Quarter-by-quarter ownership of Nektar Therapeutics (NKTR) shares owned by Barclays from 13F filings

Historical chart of Barclays investment in Nektar Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Nektar Therapeutics held by Barclays consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nektar Therapeutics by Barclays

Quarter filed Position value Share count Share price at filing
2025-09-30 $949k 17k 56.90
2025-06-30 $233k 9.0k 25.82

More positions owned by Barclays

Microsoft Corporation (MSFT)
SPDR S&ampP 500 ETF TR Fund (SPY)
Invesco Qqq Tr Fund (QQQ)
NVIDIA Corporation (NVDA)
Ishares Tr Fund (IWM)
Apple (AAPL)
Tesla Opt Put Option (TSLA)
Amazon Opt Call Option (AMZN)
Alphabet Opt Call Option (GOOGL)
Broadcom Opt Call Option (AVGO)
Facebook Inc cl a (META)
Ishares Tr Opt Call Option (HYG)
JPMorgan Chase & Co. (JPM)
Alphabet Opt Put Option (GOOG)
Berkshire Hathaway Inc Del Opt Put Option (BRK.B)

View all positions for Barclays

Top funds holding Nektar Therapeutics

Susquehanna International
BVF
Vanguard Group
Citadel Advisors
Farallon Capital Management
BlackRock
Millennium Management
Two Sigma Investments
Nantahala Capital Management
22NW
Emerald Advisers
Leucadia National Corporation
Dr. Jeffrey R. Jay, M.D.
PRIMECAP Management Company
Renaissance Technologies

View all funds holding Nektar Therapeutics